HIPK3

Homeodomain-interacting protein kinase 3 · Q9H422 · HIPK3 on Sugi Atlas →

3,133 patent compounds predicted against HIPK3, 1,994 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2465313	0.40	5/20
SCHEMBL2458435	0.47	4/20
SCHEMBL3490862	0.41	4/20
SCHEMBL3510580	0.43	3/20
SCHEMBL3490309	0.42	3/20
Azd-1208 (SCHEMBL1580644)	1.00	2/20
Azd-1208 (SCHEMBL1580646)	1.00	2/20
SCHEMBL1580546	0.74	2/20
SCHEMBL1580547	0.74	2/20
SCHEMBL1580738	0.74	2/20
SCHEMBL1580740	0.74	2/20
SCHEMBL1581733	0.74	2/20
SCHEMBL1581735	0.74	2/20
SCHEMBL1581737	0.74	2/20
Hydrochloric Acid (SCHEMBL2420968)	0.72	2/20
Hydrochloric Acid (SCHEMBL2420971)	0.72	2/20
Hydrochloric Acid (SCHEMBL2420975)	0.72	2/20
Hydrochloric Acid (SCHEMBL2427790)	0.72	2/20
Hydrochloric Acid (SCHEMBL2427794)	0.72	2/20
Hydrochloric Acid (SCHEMBL2427795)	0.72	2/20

Clinical trials — most relevant to HIPK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Epithelioid Haemangioendothelioma Observational Study	nan	RECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Genetic Mechanisms and Additional Risk Factors Underlying Hip Dysplasia	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia	nan	UNKNOWN
A Study of the Genetic Analysis of Brain Disorders	nan	COMPLETED
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs	nan	COMPLETED
Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs	nan	WITHDRAWN
Family Blood Pressure Program - GenNet Network	nan	COMPLETED
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science	nan	RECRUITING
Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients	nan	COMPLETED
Family Blood Pressure Program - SAPPHIRe Network	nan	COMPLETED
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma	nan	UNKNOWN
Use of miRNAs in Growth Hormone Deficiency (GHD)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HIPK3 binder may also engage these)

Protein	Name	Similarity
Q9ERH7	—	1.000	Q9ERH7 →
O88850	—	1.000	O88850 →
HIPK1	Homeodomain-interacting protein kinase 1	0.998	landscape →
Q9QZR5	—	0.996	Q9QZR5 →
HIPK2	Homeodomain-interacting protein kinase 2	0.996	landscape →
O88904	—	0.993	O88904 →
Q7Z353	—	0.992	Q7Z353 →
A4L9P5	—	0.991	A4L9P5 →
B2GUN4	—	0.991	B2GUN4 →
Q9WUM7	—	0.989	Q9WUM7 →
E1BZ85	—	0.989	E1BZ85 →
Q9Y4F3	—	0.988	Q9Y4F3 →
Q14B70	—	0.988	Q14B70 →
O14607	—	0.988	O14607 →
Q9H4I2	—	0.988	Q9H4I2 →
Q6GPJ8	—	0.987	Q6GPJ8 →
Q8VIG2	—	0.987	Q8VIG2 →
B8A5Y1	—	0.987	B8A5Y1 →
A0AVK6	—	0.986	A0AVK6 →
E1BKK0	—	0.986	E1BKK0 →
Q5ZKW8	—	0.986	Q5ZKW8 →
Q5HZL1	—	0.986	Q5HZL1 →
Q58FA4	—	0.985	Q58FA4 →
Q8HWS3	—	0.985	Q8HWS3 →
Q8BJ34	—	0.985	Q8BJ34 →
Q8BHZ4	—	0.985	Q8BHZ4 →
Q6ZU67	—	0.985	Q6ZU67 →
E1BE02	—	0.985	E1BE02 →
Q96T21	—	0.984	Q96T21 →
Q0VEE6	—	0.984	Q0VEE6 →